Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the… Read more
Shield Therapeutics plc (SHIEF) - Total Assets
Latest total assets as of June 2025: $62.10 Million USD
Based on the latest financial reports, Shield Therapeutics plc (SHIEF) holds total assets worth $62.10 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shield Therapeutics plc - Total Assets Trend (2015–2024)
This chart illustrates how Shield Therapeutics plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shield Therapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Shield Therapeutics plc's total assets of $62.10 Million consist of 66.0% current assets and 34.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.4% |
| Accounts Receivable | $12.28 Million | 21.4% |
| Inventory | $5.66 Million | 9.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $18.17 Million | 31.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Shield Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shield Therapeutics plc's current assets represent 66.0% of total assets in 2024, a decrease from 81.5% in 2015.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2024, down from 25.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 17.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 31.6% of total assets.
Shield Therapeutics plc Competitors by Total Assets
Key competitors of Shield Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Shield Therapeutics plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shield Therapeutics plc generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shield Therapeutics plc is currently not profitable relative to its asset base.
Shield Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.83 | 1.05 | 3.46 |
| Quick Ratio | 0.69 | 0.90 | 2.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.64 Million | $ 1.29 Million | $ 6.82 Million |
Shield Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Shield Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 86.73 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 17.8% |
| Total Assets | $57.48 Million |
| Market Capitalization | $13.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shield Therapeutics plc's assets below their book value (0.24 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shield Therapeutics plc's assets grew by 17.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shield Therapeutics plc (2015–2024)
The table below shows the annual total assets of Shield Therapeutics plc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $57.48 Million | +17.79% |
| 2023-12-31 | $48.80 Million | +121.07% |
| 2022-12-31 | $22.07 Million | -50.30% |
| 2021-12-31 | $44.41 Million | +36.54% |
| 2020-12-31 | $32.53 Million | -10.44% |
| 2019-12-31 | $36.32 Million | -16.28% |
| 2018-12-31 | $43.38 Million | -3.53% |
| 2017-12-31 | $44.97 Million | -14.15% |
| 2016-12-31 | $52.38 Million | +1731.61% |
| 2015-12-31 | $2.86 Million | -- |